Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Oncology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Oncology Other
    Annual Report Finds Declines in Cancer Incidence and Death in US, But Wide Variation in Lung Cancer Trends - (DGNews)
    Clinical Guidelines Issued on the Diagnosis, Management of Metastatic Spinal Cord Compression - (DGNews)
    Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients: A Meta-analysis - (JAMA)
    Effect of combined folic acid, vitamin B6, and vitamin B12 on cancer risk in women: a randomized trial - (JAMA)
    Folic Acid, B Vitamins Have No Effect on Cancer Risk in Women at High Risk of CVD - (DGNews)

    News archive

     Recent webcasts/CME - Oncology Other

    Webcasts/CME archive

     Recent cases - Oncology Other
      Experience with Adjuvant Chemotherapy for Pseudomyxoma Peritonei Secondary to Mucinous Adenocarcinoma of the Appendix with Oxaliplatin / Fluorouracil /Leucovorin (FOLFOX4)
      Transsacral Colon Fistula : Late Complication after Resection, Irradiation and Free Flap Transfer of Sacral Chondrosarcoma
      Metastatic Colorectal Cancer to a Primary Thyroid Cancer
      Inflammatory Myofibroblastic Tumor of Epididymis: A Case Report and Review of Literature
      Intravascular Leiomyosarcoma of the Brachiocephalic Region - Report of an Unusual Tumour Localisation: Case Report And Review of the Literature

      Cases archive
        




      my personal edition > oncology other > news
      divider

        E-Mail this DGReview to a colleague

      DGReview


      Combined Doxorubicin/Cisplatin Increases Response Rate In Endometrial Adenocarcinoma

      A DGReview of :"Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group."
      Annals of Oncology

      03/04/2003
      By Elda Hauschildt


      Combining doxorubicin with cisplatin produces a significantly higher response rate in patients with endometrial adenocarcinoma than does doxorubicin monotherapy, research from Switzerland indicates.

      Investigators from Hopital Cantonal Universitaire in Geneva report a modest survival benefit is achieved, especially in patients who have a good performance status. Median overall survival was nine months in combination therapy patients and seven months in monotherapy patients. They add that toxicity is higher but acceptable with combination therapy.

      A total of 177 patients with histologically proven advanced and/or recurrent endometrial adenocarcinoma were enrolled. Median follow-up was 7.1 years. Participants were chemotherapy naïve.

      Treatment was administered every four weeks. It was made up of either 60 mg/m² doxorubicin alone or with 50 mg/m² of cisplatin added.

      Results indicate 39 patients (43%) receiving doxorubicin/cisplatin responded, including 13 with complete responses and 26 with partial responses. This compared with 15 patients (17%) who responded to doxorubicin monotherapy. A total of eight monotherapy patients were complete responders and seven had partial responses.

      Combination therapy was more toxic. White blood cell toxicity grades 3 and 4 occurred in 55% of combination therapy patients and in 30% of monotherapy patients.

      There were two main forms of non-haematological toxicity. Grades 3 and 4 alopecia occurred in 72% of combination therapy patients and in 65% of monotherapy patients. Nausea/vomiting was observed in 36% of combination therapy patients and 12% of monotherapy patients.

      World Health Organisation performance status was found to be statistically significant as a prognostic factor for survival.
      Annals of Oncology, 2003;14:3:441-448. "Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group."

      E-Mail this DGReview to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send